Clinical trials: Anti Vascular Endothelial Growth Factor
Choroidal Neovascularization, Punctate Inner Choroidopathy
Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor
To evaluate the long-term outcome of active choroidal neovascularization (CNV) in punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) after anti-vascular endothelial factor treatment.
- Trial name
- NCT03793400
- Testing
- Bevacizumab Injection
- Where
- Taiwan
- Volunteers
- 22 people
- Sponsor
- Changhua Christian Hospital
Retinal Telangiectasis, Coats Disease
Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease
Coats disease is a predominantly unilateral progressive retinal vascular disease, characterized by retinal telangiectasias with intra- or subretinal exudate deposits, which can lead to retinal detachment and one-sided blindness.
- Trial name
- COATS-VEGF (NCT03940690)
- Testing
- Anti-VEGF injections of bevacizumab, Laser
- Where
- 6 sites in France
- Volunteers
- 18 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic
Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects
This is a randomized, double-blind, single-dose, parallel-group study comparing pharmacokinetic characteristics, safety , tolerability and immunogenicity of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth…
- Conditions
- Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent
- Trial name
- NCT05110118
- Testing
- LY01008, Avastin
- Where
- China
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Shandong Boan Biotechnology Co., Ltd
Diabetic Retinopathy (DR), Diabetic Macular Edema (DME)
Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery
Objective of this randomised controlled trial is to compare the efficacy of a single per operative anti VEGF injection with repeated postoperative anti VEGF injections in the prevention of diabetic retinopathy progression after…
- Conditions
- Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Cataract, Phacoemulfisication+IOL Implantation
- Trial name
- NCT07301775
- Testing
- Aflibercept (Eylea)
- Where
- 2 sites in Pakistan
- Volunteers
- 166 people
- Sponsor
- Ahmad Zeeshan Jamil
Macular Edema Due to Type 2 Diabetes Mellitus
Efficacy Analysis of Anti-VEGF Drugs Combined With Micropulse Laser in the Treatment of Diabetic Macular Edema
The goal of this clinical trial is to clarify the efficacy of anti-vascular endothelial growth factor (anti-VEGF) drugs combined with subthreshold micropulse laser (SML) therapy on retinal function and anatomical recovery in…
- Trial name
- VEGF (NCT05759884)
- Testing
- Anti-VEGF, subthreshold micropulse laser
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Age-related Macular Degeneration
Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Age-related macular degeneration, a leading cause of blindness, is caused by an abnormal growth of the vessels beneath the retina.
- Trial name
- NCT00539734
- Testing
- ranibizumab
- Where
- Thailand
- Volunteers
- 25 people
- Sponsor
- Prince of Songkla University
Diabetic Macular Edema
DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME
Both aflibercept and bevacizumab have been shown to improve vision in eyes with DME. In eyes with DME and at least moderate vision loss, both aflibercept and bevacizumab were also shown to be successful in many eyes.
- Trial name
- DRCR AC (NCT03321513)
- Testing
- intravitreous aflibercept, Bevacizumab + Deferred Aflibercept Group
- Where
- 54 sites in United States
- Volunteers
- 270 people
- Sponsor
- Jaeb Center for Health Research
MSI-H Colorectal Cancer
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
This is a trial of Regorafenib in combination with pembrolizumab for patients with MSI-H colorectal cancer consisting of lead-in phase examining preliminary efficacy and safety, followed by a randomized phase to further examine…
- Trial name
- NCT06006923
- Testing
- Regorafenib, Pembrolizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Anwaar Saeed
Kidney Injury, Proteinuria
Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury
The purpose of this study is to test the hypothesis that isosorbide mononitrate prevents deterioration of renal function in patients receiving anti-angiogenic therapies that target vascular endothelial growth factor (VEGF).
- Conditions
- Kidney Injury, Proteinuria, Hypertension
- Trial name
- NCT04051957
- Testing
- Isosorbide Mononitrate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The University of Texas Health Science Center, Houston
Leukemia, Myelodysplastic Syndromes
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
RATIONALE: Monoclonal antibodies such as bevacizumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00015951
- Testing
- bevacizumab, cytarabine, mitoxantrone hydrochloride
- Where
- 3 sites in United States
- Sponsor
- University of Maryland, Baltimore
Renal Cell Carcinoma, Kidney Cancer
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
The goal of this clinical research study is to learn if the combination of 3 drugs (gemcitabine, capecitabine, and bevacizumab) can help to control metastatic or unresectable renal cell carcinoma.
- Trial name
- NCT00496587
- Testing
- Capecitabine, Gemcitabine, Bevacizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Neovacular Age-related Macular Degeneration
UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)
This study assessed systemic vascular endothelial growth factor (VEGF) level in patients with neovascular Age-related Macular Degeneration following treatment with Ranibizumab or Aflibercept.
- Trial name
- UNRAVEL (NCT01988662)
- Testing
- Neovascular Age-related Macular Degeneration
- Where
- 24 sites in Israel, Malaysia and 5 more
- Volunteers
- 205 people
- Sponsor
- Novartis Pharmaceuticals
Punctate Inner Choroidopathy
Long-term Outcome of Zonal Outer Retinopathy in Punctate Inner Choroidopathy or Multifocal Choroiditis
To report the long term prognosis in patients with punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) and associated zonal outer retinopathy (ZOR).
- Trial name
- NCT03897192
- Testing
- Bevacizumab
- Where
- Taiwan
- Volunteers
- 14 people
- Sponsor
- Changhua Christian Hospital
Age-related Macular Degeneration (ARMD), Choroidal Neovascularization
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly…
- Conditions
- Age-related Macular Degeneration (ARMD), Choroidal Neovascularization, Anti-vascular Endothelial Growth Factor
- Trial name
- NCT07187804
- Testing
- Intravitreal faricimab injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Kim's Eye Hospital
Age Related Macular Degeneration
Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter
Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial.
- Trial name
- NCT01626339
- Testing
- Intravitreal Ranibizumab, Intravitreal bevacizumab
- Where
- Malaysia
- Volunteers
- 30 people
- Sponsor
- University of Malaya
Diabetic Macular Edema
Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant
The dexamethasone 700 μg intravitreal implant (DEX-I) delivers dexamethasone gradually to the retina over time. It is an approved drug for the treatment of DME.
- Trial name
- P23-380 - INIT (NCT05978622)
- Where
- 54 sites in Belgium, China and 7 more
- Volunteers
- 236 people
- Sponsor
- AbbVie
Ocular Melanoma
Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma
The reference treatment of ocular melanoma is a conservative treatment by proton therapy. Its goal is to treat the tumor while preserving the eyeball and visual acuity.
- Trial name
- PROTECT (NCT03172299)
- Testing
- Aflibercept Injection, False injection
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Exudative Age Related Macular Degeneration
Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
Optical Coherent Tomography Angiography (OCTA)-Directed PDT Triple Therapy for Treatment-Naïve Patients with Exudative Age-related Macular Degeneration (ARMD) versus Standard of Care Anti-VEGF Monotherapy
- Trial name
- NCT04075136
- Testing
- Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Kaposi's Sarcoma, HIV Infections
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
This study will examine the safety and effectiveness of the experimental drug bevacizumab for treating both non-acquired immune deficiency syndrome (AIDS) and AIDS-associated Kaposi's sarcoma (KS).
- Conditions
- Kaposi's Sarcoma, HIV Infections, HIV Seronegativity
- Trial name
- NCT00055237
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Breast Cancer, Triple Negative Breast Cancer
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and…
- Conditions
- Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
- Trial name
- NCT06449222
- Testing
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel
- Where
- 31 sites in United States, Australia and 2 more
- Volunteers
- 83 people
- Sponsor
- BioNTech SE